Industry News
Eli Lilly drug tirzepatide, marketed as Zepbound for weight management
Apr 17, 2024

INDIANAPOLIS, IN – Eli Lilly and Company (NYSE: LLY) announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the severity of obstructive sleep apnea (OSA) and the effectiveness of treatment outcomes. Tirzepatide is the only approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) treatment for chronic weight management, commercialized as Zepbound® in the U.S. and Mounjaro® in some global markets outside the U.S.

SURMOUNT-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were not on positive airway pressure (PAP) therapy for 52 weeks. For the efficacy estimandi, at 52 weeks, tirzepatide led to a mean AHI reduction from baseline of 27.4 events per hour compared to a mean AHI reduction from baseline of 4.8 events per hour for placebo. In key secondary outcomes, tirzepatide led to a mean AHI reduction from baseline of 55.0% compared to 5.0% from baseline for placebo; tirzepatide also led to a mean body weight reduction of 18.1% from baseline, compared to 1.3% from baseline for placebo.

SURMOUNT-OSA Study 2 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were on and planned to continue to use PAP therapy for 52 weeks. In this population for the efficacy estimand, at 52 weeks, tirzepatide led to a mean AHI reduction from baseline of 30.4 events per hour compared to a mean AHI reduction from baseline of 6.0 events per hour for placebo. In key secondary outcomes, tirzepatide led to a mean AHI reduction from baseline of 62.8% compared to 6.4% from baseline for placebo; tirzepatide also led to a mean body weight reduction of 20.1% from baseline, compared to 2.3% from baseline for placebo.

The weight loss observed at 52 weeks with tirzepatide (10 mg and 15 mg) across the two studies was nearly 20% in a patient population that was comprised of approximately 70% males, who are known to achieve less weight loss with incretin therapy than females.

OSA is a sleep-related breathing disorder characterized by complete or partial collapses of the upper airway during sleep, which can lead to apnea or hypopnea and a potential decrease in oxygen saturation and/or waking from sleep. OSA can have serious cardiometabolic complications, contributing to hypertension, coronary heart disease, stroke, heart failure, atrial fibrillation and type 2 diabetes.

"OSA impacts 80 million adults in the U.S., with more than 20 million living with moderate-to-severe OSA. However, 85% of OSA cases go undiagnosed and therefore untreated," said Jeff Emmick, MD, Ph.D., senior vice president, product development, Lilly. "Addressing this unmet need head-on is critical, and while there are pharmaceutical treatments for the excessive sleepiness associated with OSA, tirzepatide has the potential to be the first pharmaceutical treatment for the underlying disease."

Hospital Pharmaceuticals
Apr 15, 2024

LOUISVILLE, KY — ScionHealth announced today they will begin purchasing certain bulk drugs from Mark Cuban’s Cost Plus Drug Company (“Cost Plus Drugs”) and delivered to Safecor Health’s SafecorLogics program. The integrated approach, combining the expertise of three organizations, will enable ScionHealth to deliver exceptional value to patients while ensuring the sustainability of its healthcare delivery model.

Cost Plus Drugs was launched in January 2022 with the mission of providing cheaper pharmaceuticals by eliminating middlemen and offering a transparent pricing model. The company’s Cost Plus Drugs Marketplace launched in 2023 to bring this same philosophy to healthcare business purchasers. “Everyone should be able to access their prescriptions at affordable and transparent prices,” said Dr. Alexander Oshmyansky, CEO at Cost Plus Drugs. “We are thrilled to work with ScionHealth as one of our initial health system partnerships and look forward to our work together with their team and Safecor Health.”

Since September of 2023, ScionHealth has worked with Safecor Health as a strategic supply chain partner through Safecor Health’s SafecorLogics program. SafecorLogics was developed to help healthcare systems centralize their own unit-dose supply chains, giving them greater cost savings and mitigating waste while optimizing staffing and operations. ScionHealth expanded its utilization of the program in January of 2024.

“Across the industry and particularly in hospital settings, we are facing the challenges of rising drug and supply costs and navigating staffing shortages,” said Rob Jay, ScionHealth’s Chief Executive Officer. “ScionHealth is continually looking for innovative approaches to address these issues while advancing the delivery of high-quality, patient-centered care and well-being to our communities. SafecorLogics has already been an effective solution to help us address these challenges. Now, by introducing Cost Plus Drugs, we are confident we’ll see even more success managing drug costs and enhancing care delivery across the ScionHealth network.”

Steve Fischbach, Safecor Health’s Chief Executive Officer, echoed this sentiment, saying “We are proud to partner with innovative companies like ScionHealth and we are excited to expand that partnership with products from Cost Plus Drugs. It’s a great fit for the SafecorLogics program and we’re sure it will lead to meaningful savings for ScionHealth.”

The drugs ScionHealth purchases in bulk from Cost Plus Drugs will be delivered to Safecor Health's unit-dose packaging centers where they will be packaged, stored, and shipped same-day as requested by ScionHealth's locations.

interim CEO
Apr 04, 2024

Anders Hedlund is currently the CEO of Nolsterby Invest AB, the largest shareholder in Pharmacolog. Nolsterby Invest AB is an investment company in the healthcare sector and has been invested in Pharmacolog since 2017. Since 2023, Anders Hedlund is also a current Board Member of Pharmacolog, a position he plans to maintain.

Erik Hedlund, Chairman of the Board and main owner of Pharmacolog: "We are in a transformational process to become a serial acquirer within the healthcare sector. There is a lot of work to be done although we have made progress during the quarter by, for instance, divesting the Druglog product line. Recently, we also announced our intention to change the name of the company. Anders Hedlund’s main task will be to lay the ground for the new business direction. His extensive experience and network in the healthcare and financial industry make him suitable for this task.”

emergency response plan
Apr 02, 2024

IRVING, TX – Vizient, Inc. released recommendations focused on mitigating common risks, identifying national guidelines and utilizing existing resources to ensure preparedness for an active shooter event. The recommendations were made by a task force of 40 Vizient network executives from 27 organizations across the country. The recommendations and rationales bring attention to organizational tactics that were found by the task force to be lacking or inconsistent. View active shooter preparedness resources.

"It is an uncomfortable topic to discuss but it is vital that hospitals address the issue of a potential active shooter event," said Susan Chishimba, Vizient Member Networks senior director. "Planning for the unthinkable will invariably save lives."

The recommendations are based in part on the results of a recent Vizient provider customer health system survey that revealed disparities in active shooter protocols. While 98% of hospital system respondents said they have enacted an active shooter protocol, preparedness varied. Only 24% have discussed a dedicated plan to ensure continuity of care for critically ill patients. Of those, very few use a "secure-preserve-defend" doctrine in which staff first prioritize locking down or barricading their patient care areas. The results of the survey are published in the American Journal of Disaster Medicine. View a summary of the survey findings, Assessing Active Shooter Preparedness in U.S. Hospital Systems.

The recommendations from the task force focus on appropriate communication, secure access, management of critically ill patients who are unable to run, hide and fight, and include tactics for addressing post-event trauma. The  online resources, which comprise recommendations and rationales for communication, physical security, plan and response, drills and simulations and a post-event response, include:

  • Using appropriate language when broadcasting an event, with attention to both internal and external communication.
  • Integrating access control, video surveillance, alarms, and other supportive technology to reduce the risk of active shooters gaining access to secure areas.
  • Investing in shot-detection technology that would alert local law enforcement as soon as shots are fired.
  • Considering the need for hemorrhage control procedure and supplies as a critical element of an organization’s response plan.
  • Focusing on the importance of post-event recovery in order to restore safety, rebuild confidence and foster resilience.

"Active shooter events are a tragic and unfortunate reality," said Jodi Eisenberg, associate vice president, Vizient Member Networks. "It’s critically important to have a comprehensive plan in place — even if it’s one you hope you never have to use."

View active shooter preparedness resources.

breast cancer
Apr 02, 2024

TOKYO and BASKING RIDGE, NJ – Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. 

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca. 

The Prescription Drug User Fee Act (PDUFA) date, the U.S. Food and Drug Administration (FDA) action date for its regulatory decision, is January 29, 2025. 

The BLA is based on results from the pivotal TROPION-Breast01 phase 3 trial, which were presented at a Presidential Symposium at the European Society for Medical Oncology (#ESMO23) 2023 Congress and in an oral presentation at the 2023 San Antonio Breast Cancer Symposium (#SABCS23). In the trial, datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoint of progression-free survival (PFS) compared to investigator’s choice of chemotherapy in patients with unresectable or metastatic HR positive, HER2 negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy. For the dual primary endpoint of overall survival (OS), interim results numerically favored datopotamab deruxtecan over chemotherapy but were not mature at the time of data cut-off. The trial is ongoing and OS will be assessed at future analyses. The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified. The most common grade 3 or higher treatment-related adverse events in the datopotamab deruxtecan and chemotherapy arms, respectively, were neutropenia (1% vs. 31%), stomatitis (6% vs. 3%), fatigue (2% vs. 2%) and anemia (1% vs. 2%). 2 

“The FDA’s acceptance of the BLA brings us closer to providing patients with previously treated HR positive, HER2 negative breast cancer an alternative option to conventional chemotherapy earlier in the metastatic setting,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “Following our recently accepted application for advanced nonsquamous non-small cell lung cancer in the U.S., along with additional regulatory reviews underway in China, the EU, Japan and other regions, we are working swiftly to bring datopotamab deruxtecan as a potential new treatment option to patients around the world.” 

“Despite marked progress in the treatment of HR positive, HER2 negative breast cancer, most patients with advanced disease develop endocrine resistance and face the prospect of one or several lines of chemotherapy,” said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology R&D, AstraZeneca. “If approved, datopotamab deruxtecan has the potential to provide these patients an efficacious and better tolerated alternative to conventional chemotherapy.” 

An additional BLA for datopotamab deruxtecan based on results from the pivotal TROPION-Lung01 phase 3 trial is under review in the U.S. for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy. Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.

product recall
Mar 27, 2024

BRIDGEWATER, NJ - Amneal Pharmaceuticals, LLC. (Amneal) is voluntarily recalling 4 lots (see table below) of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5mL packaged in 80 mL, 150 mL, or 300 mL pack sizes, to the Consumer Level.  Some bottles may have been overfilled which can result in an over potent dosing regimen.   The recommended maximum daily dose allowance for this product is up to 2gm/day and patients prescribed a dosing regimen of 500 mg/10mL would exceed this daily allowance, which may be harmful to patients with renal insufficiency.   The error occurred during the manual bottle filling stage of manufacturing. 

Risk Statement:  Adult patients who are prescribed the maximum daily dose of up to 2 grams per day of Vancomycin Hydrochloride for oral solution, USP 250 mg/5mL, may receive up to 4 grams of oral vancomycin per day because of the overfilled bottle.  Some patients with inflammatory disorders of the intestinal mucosa also may have significant systemic absorption of vancomycin. These patients may be at risk for the development of adverse reactions associated with higher doses of vancomycin oral solution. Worsening renal function could be associated with electrolyte abnormalities such as high potassium leading to cardiac arrest.  To date, Amneal has not received any reports of adverse events that have been confirmed to be directly related to this recall.

Vancomycin Hydrochloride for Oral Solution, USP, 250mg/5mL, is administered orally for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic- associated pseudomembranous colitis caused by C. difficile

The Vancomycin HCl for Oral Solution, USP, 250 mg/5mL subject to the recall, are identified by the NDC numbers stated on the product label.  The following lot numbers of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5mL are included in this recall.  

Vancomycin Hydrochloride for Oral Solution, USP, 250mg/5mL

NDC No.LotExpiration DatePack Size
69238-2261-322613003A09/202580 mL
69238-2261-722613004A09/2025150 mL
69238-2261-722613005A09/2025150 mL
69238-2261-522613005B09/2025300 mL

The affected Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5mL lots were distributed Nationwide in the USA directly to Wholesalers and Distributors.  The Lots were distributed between 11/09/2023 and 2/20/2024.   

Amneal is notifying its direct customers via mail (UPS Standard Overnight) by mailing a recall notification letter and is arranging for the return of the recalled products. Anyone with an existing inventory of the product being recalled should examine the product and quarantine any of the recalled lots immediately.

Customers who purchased the impacted product directly from Amneal may call Amneal at
1 833-582-0812 Monday – Friday, 8:00 am – 5:00 pm, EST, or email to for further information.   

Retailers who have Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5mL, which are being recalled, should examine their inventory and cease dispensing any of the impacted lots and contact Amneal directly via email at or by telephone 1833-582-0812 Monday – Friday, 8:00 am – 5:00 pm, EST, for information and instructions for the product return.   

Consumers who have Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/mL should examine the bottle, cease using the product if the lot number is listed on the recall and contact Amneal via telephone or email for recall information and for product return instructions.  Consumers may call Amneal at 1 833-582-0812 Monday – Friday, 8:00 am – 5:00 pm, EST, or email for further information and instructions for the product return.  Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

If you would like to report any adverse reactions or quality problems experienced with the use of this product you may contact Amneal Drug Safety by phone at 1-877-835-5472, Monday - Friday, 8:00 am – 6:00 pm, EST, or via e-mail at

Any adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Mar 25, 2024

NORTH CHICAGO, IL & NEW YORK, NY - AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.

"With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn's disease," said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie.

"This announcement is a testament to Landos' talented team and their commitment to our mission of creating oral treatments that can address a therapeutic gap," said Gregory Oakes, president and chief executive officer, Landos. "NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn's disease. With AbbVie's therapeutic area leadership and expertise in global development, they are the right company to further advance NX-13."

NLRX1 regulates immunometabolism and inflammation, and its activation impacts multiple mechanisms of inflammatory bowel disease (IBD) pathogenesis. The randomized controlled Phase 2 NEXUS clinical trial evaluating NX-13 in UC is currently enrolling patients in the United States and Europe (NCT05785715).

Under the terms of the agreement, AbbVie will acquire Landos at a price of $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos' stockholders.

WVU Pharmacists
Mar 21, 2024

An artificial intelligence tool West Virginia University health data scientists are developing could lessen medication errors that send recently discharged patients back to the hospital while reducing health care costs.

At least 1.5 million people are harmed by medication errors every year, according to the Academy of Managed Care Pharmacy, and the cost for treating these drug-related injuries occurring in hospitals alone is estimated at $3.5 billion annually.

“Because of this we need to provide better tools to our clinicians,” said Abdullah Al-Mamun, assistant professor in the WVU School of Pharmacy Department of Pharmaceutical Systems and Policy, who is leading the project. “We will develop a tool where we’ll go through each of the patient’s records for the medication reconciliation process. Our goal is to build an alert system that shows if the patient has a higher chance of getting readmitted.”

Medication reconciliation is a standard practice clinicians perform before patients are discharged from the hospital. The process is a review of prescriptions and over-the-counter treatments they were taking prior to and during their stay. The result should be a comprehensive list of what to take — and not take — along with specific dosages when they return home. However, Mamun said since information is gathered from multiple clinicians to make care recommendations, the procedure oftentimes becomes convoluted.

“This is where 85% of the errors happen,” Mamun said. “During a patient’s time in the hospital, medications are changed to improve the outcome. The patient cannot go home with the same amounts of medications they were given in the hospital. There should be an adjustment.”

As a remedy, Mamun points to studies showing a 50% reduction in 30-day readmission rates when a transition-of-care pharmacist took over medication reconciliation. His project aims to make the pharmacist’s job more efficient and effective through this AI-driven tool.

Mamun explained hospitals use electronic data systems containing information on medications and billing, along with notes from physicians, nurses and pharmacists. For medication reconciliation, a pharmacist spends between 30 to 50 minutes reviewing those records for each discharge patient, which can number around 200 a day in a facility the size of J.W. Ruby Memorial Hospital.

Mamun and members of his HealBig research lab want to streamline the process.

“That’s where the AI comes in,” Mamun said. “It will pull all these data and using different algorithms will build a profile for the patient. That will make the process more accurate and much faster and improve medication safety.”

The HealBig team will employ the AI method of deep learning for natural language processing to allow the program to understand certain words and phrases in clinicians’ notes. Based on factors — such as medical history and current physical condition — in each patient’s profile, the tool will also be able to determine the risk of readmission and create an alert system for pharmacists.

“Let’s say patient X is feeling better, but my tool says he has a 90% chance of coming back to the hospital in 30, 60 or 90 days. That would raise a flag,” Mamun said. “The pharmacist could go back to the interprofessional care team so they could go over the patient’s profile one more time to see if they should keep him in the hospital a couple more days. Something like that could save a patient’s life.”

The use of AI technology will also benefit students in Mamun’s lab by giving them the experience of learning data science tools they can use later in their professional careers.

“They will learn different dimensions of how to ultimately improve patient outcomes,” Mamun said. “When they are exposed to projects like this, they become more motivated to do research.”

Ki Jin Jeun, a graduate research assistant majoring in health services and outcomes research, will work on the statistical analyses. Other students in the WVU Pharmacy doctoral programs will join the project as it progresses.

With a two-year, $100,000 grant from the American College of Clinical Pharmacy, Mamun is working on the project with Kazuhiko Kido, clinical associate professor.

The team will first develop an alert system prototype. Mamun said the next step will be to integrate the tool into a hospital’s electronic data system and run a pilot test. For that phase, the team plans to seek a larger grant.

“The next phase will be challenging because that’s where the real interaction comes into the system,” Mamun said. “We will need a lot of resources and clinical experts. It’s very exciting to bring health data science and AI technologies into the medical field, especially in pharmacy. This will help payers, medical providers and, ultimately, clinicians to make better decisions.”    

UNC Health Pardee
Mar 21, 2024

HENDERSON, NC - UNC Health Pardee is pleased to announce the opening of Pardee Rx, a community pharmacy for Pardee patients, teammates, and community members. Pardee Rx offers a wide variety of generic and brand-name drugs as well as a complete selection of over-the-counter medications, vitamins, health and wellness needs, pediatric care items, and common medical supplies. The pharmacy is now open adjacent to the Pardee BlueMD -1027 Fleming St. primary care office in Hendersonville.

With the opening of Pardee Rx, Pardee is also pleased to welcome pharmacists Bryce Caldwell, PharmD, and Kenesha Smith, PharmD, to the team. Caldwell and Smith are available for consultations, whether to provide an answer to a question or education about medication.

“Our commitment to the community is what makes Pardee Rx different from other pharmacies,” said Johnna Reed, Chief Administrative Officer, UNC Health Pardee. “We are built on the strength of a team that includes physicians, pharmacists, case workers, nurses, medical assistants, and others who are focused on the goal of a healthy community. From medical assistance programs to affordable prescriptions, Pardee Rx is here for you.”

Through Pardee’s affiliation with Pardee BlueMD and its federally qualified health center (FQHC) status, the pharmacy can offer services to all patients, regardless of ability to pay. The pharmacy is open Monday through Friday from 8am - 6pm. For more information or questions call 828-435-8142.

UNC Health Pardee is a not-for-profit community healthcare organization and is managed by UNC Health. The hospital, founded in 1953, is licensed for 222 acute care beds. Pardee has several locations separate from the main campus, including a comprehensive physician practice network, a cancer center, four urgent care locations and six orthopedic clinics. For more information or to find a physician, visit

Mar 20, 2024

SCHAUMBURG, IL - Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the United States as a therapeutic equivalent generic for Lasix® for Injection (furosemide) approved by the U.S. Food and Drug Administration. Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired.

“The launch of Furosemide for Injection builds on the two launches announced earlier this week and further demonstrates the speed at which we are progressing the business,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “The reception by potential partners and investors to Avenacy at DCAT has been outstanding and, with five products now launched since our formation in October, we look forward to continuing to execute against our goal of launching more than 20 products this year.”

Avenacy's Furosemide will come in packs of 25 units of 100 mg/10 mL doses. In line with Avenacy’s mission to champion patient safety and streamline patient care, Furosemide for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection. Avenacy will begin shipping Furosemide for Injection to wholesale partners next week. The Company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.

Furosemide for Injection had U.S. sales of approximately $33 million for the twelve months ending in June 2023.1

To learn more about Avenacy’s products or the Company’s exciting growth plans for 2024, please see the Avenacy management team at DCAT Week 2024 taking place in New York City from March 18-21st. To request a meeting with a member of the Avenacy team, please reach out to

Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs.

Please see link for Full Prescribing Information including the Boxed Warning.

Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical.

Lasix® is a registered trademark of Sanofi S.A.

1Source: IQVIA